Sirtuin Modulator Companies for Parkinson's Disease

Overview

This page indexes companies developing sirtuin-targeted therapies for Parkinson's disease. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that play critical roles in mitochondrial function, stress resistance, and cellular homeostasis—all processes impaired in Parkinson's disease.

For the main mechanism page, see [SIRT1 Activators for Parkinson's Disease](/mechanisms/sirt1-activators-parkinsons).

Therapeutic Approaches

SIRT1 Activation

• Direct SIRT1 activators (resveratrol, synthetic compounds)
• NAD+ precursors (nicotinamide riboside, NMN) that enhance SIRT1 activity indirectly
• PGC-1α deacetylation → mitochondrial biogenesis
• FOXO deacetylation → stress resistance
• α-synuclein deacetylation → reduced aggregation

SIRT2 Inhibition

• SIRT2 inhibitors reduce α-synuclein toxicity
• Protect dopaminergic neurons
• Improve motor function in PD models[@sirt2_pd]

SIRT3 Modulation

• Mitochondrial sirtuin targeting
• SOD2 activation → reduced oxidative stress
• IDH2 activation → improved mitochondrial metabolism

Company Directory

Major Pharmaceutical Companies

| Company | Focus | Programs | Page |
|---------|-------|----------|------|
| GSK (GlaxoSmithKline) | SIRT1 activators | SRT2104 (historical), SRT3025 | [GSK](/companies/gsk) |

Biotechnology Companies

Overview

This page indexes companies developing sirtuin-targeted therapies for Parkinson's disease. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that play critical roles in mitochondrial function, stress resistance, and cellular homeostasis—all processes impaired in Parkinson's disease.

For the main mechanism page, see [SIRT1 Activators for Parkinson's Disease](/mechanisms/sirt1-activators-parkinsons).

Therapeutic Approaches

SIRT1 Activation

• Direct SIRT1 activators (resveratrol, synthetic compounds)
• NAD+ precursors (nicotinamide riboside, NMN) that enhance SIRT1 activity indirectly
• PGC-1α deacetylation → mitochondrial biogenesis
• FOXO deacetylation → stress resistance
• α-synuclein deacetylation → reduced aggregation

SIRT2 Inhibition

• SIRT2 inhibitors reduce α-synuclein toxicity
• Protect dopaminergic neurons
• Improve motor function in PD models[@sirt2_pd]

SIRT3 Modulation

• Mitochondrial sirtuin targeting
• SOD2 activation → reduced oxidative stress
• IDH2 activation → improved mitochondrial metabolism

Company Directory

Major Pharmaceutical Companies

| Company | Focus | Programs | Page |
|---------|-------|----------|------|
| GSK (GlaxoSmithKline) | SIRT1 activators | SRT2104 (historical), SRT3025 | [GSK](/companies/gsk) |

Biotechnology Companies

| Company | Focus | Programs | Page |
|---------|-------|----------|------|
| ChromaDex | NAD+ precursors | NR-002 for Parkinson's | [ChromaDex](/companies/chromadex) |
| Life Biosciences | SIRT1 activator | LB-SIRT1 program | [Life Biosciences](/companies/life-biosciences) |

Research Pipeline Overview

Clinical Stage Programs

| Company | Compound | Target | Mechanism | Phase | Indication |
|---------|----------|--------|-----------|-------|------------|
| ChromaDex | NR-002 | SIRT1 (indirect) | NAD+ augmentation | Phase 2 | Parkinson's disease |
| GSK (historical) | SRT2104 | SIRT1 | Direct activation | Phase 2 | Alzheimer's disease |
| Life Biosciences | LB-SIRT1 | SIRT1 | Direct activation | Discovery | Alzheimer's/Parkinson's |

Key Mechanisms

• [SIRT1 Activators for Parkinson's Disease](/mechanisms/sirt1-activators-parkinsons)
• [Sirtuin Signaling in Parkinson's Disease](/mechanisms/sirtuin-signaling-parkinsons)
• [NAD+ Metabolism in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration)
• [Mitochondrial Biogenesis in Neurodegeneration](/mechanisms/mitochondrial-biogenesis-neurodegeneration)

Related Therapeutics

• [Sirtuin Modulators](/therapeutics/sirtuin-modulators)
• [NAD+ Boosters for Neurodegeneration](/therapeutics/nad-boosters-neurodegeneration)
• [Resveratrol and Neurodegeneration](/therapeutics/resveratrol-neurodegeneration)

Market Landscape

The sirtuin modulator field for Parkinson's disease has evolved through several phases:

Investment Trends

• Major pharma (GSK) has reduced direct SIRT1 activator investment
• Biotech focus on NAD+ augmentation (ChromaDex)
• Academic/industry partnerships for biomarker development
• Growing interest in SIRT2 inhibitors for PD

Research Gaps

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Investment Landscape: Sirtuin Therapeutics](/investment/sirtuin-therapeutics-neurodegeneration)
• [PD Pipeline](/companies/pd-pipeline)

References